MTHFR C677T Polymorphism Is Associated with the Risk of Breast Cancer among Kurdish Population from Western Iran

Abstract

Background: The key enzyme of methylenetetrahydrofolate reductase (MTHFR) is involved in DNA biosynthesis and repair. Objectives: The role of MTHFR C677T polymorphism in susceptibility to breast cancer is controversial. Methods: In the present case-control investigation, 297 individuals consisted of 100 patients with breast cancer and 197 healthy women were studied for MTHFR C677T genotypes, using PCR-RFLP method. Results: The frequency of MTHFR TT genotype was 10% in patients and 3% in controls (P = 0.008). The presence of TT genotype was associated with susceptibility to breast cancer [OR = 1.97, 95%CI: 1.16-3.36, P = 0.012]. The T allele of MTHFR was found in 30% of the patients compared to 27.6% healthy controls (P = 0.024) that enhanced the risk of breast cancer by 1.56 times (95% CI: 1.06-2.3, P = 0.024). There were 71 individuals (71%) with the age of breast cancer diagnosis ≤ 51 years old. Comparing patients with the age of cancer diagnosis ≤ 50 years old with those > 51 years old group indicated a higher frequency of MTHFR TT genotype in the latter (20.7%) compared to the first group (5.6%, P = 0.05). Conclusions: Our study demonstrated an association between the MTHFR C677T polymorphism with the risk of breast cancer among population of Western Iran. Also, our study suggests that the MTHFR TT genotype could be a risk factor for breast cancer in postmenopausal women.

Strong Correlation of MTHFR Gene Polymorphisms with Breast Cancer and its Prognostic Clinical Factors among Egyptian Females

“…Furthermore, in this study, the frequency of T allele of MTHFR C677T in patients was 54.5% vs.16.7% in controls with highly significant value (P= 0.001), indicating that the risk of breast cancer increases by 5.98 times in individual carrying the T allele. These results are supported by previous studies conducted on different populations as Indian and Moroccan suggesting that this polymorphism could be a therapeutic target for breast cancer (Waseem et al, 2016;Hardi et al, 2018;Rahimi et al, 2019). On the other hand, some previous case-control studies of: Mexican, north Indian, Turkish and Chinese population did not report any relation (Mir et al, 2008;Ramos-Silivia et al, 2015;Kaya et al, 2016;Song et al, 2016).…”

Gene-Gene Interaction Study Between Genetic Polymorphisms of Folate Metabolism and MTR SNPs on Prognostic Features Impact for Breast Cancer

“…Moreover, it is observed that the haplotype T-C-G plays a high role in metastatic lymph nodal status with strong significant association (p= 0.003). In a support from (16,33) to our data, it is reported that there were tendencies for CRC patients with mutant genotypes to have more positive lymph nodes. However, other studies showed no significant difference in genotype distribution among different phases of metastatic lymph nodes (20).…”

Association of C677T (rs1081133) and A1298C (rs1801131) Methylenetetrahydrofolate Reductase Variants with Breast Cancer Susceptibility Among Asians: A Systematic Review and Meta-Analysis

“…Biochemical Genetics (2021) 59:367-397 A NOTE: Weights are from random effects analysis Overall (I-squared = 78.9%, p = 0.000) Naushad ( 2011) Lu (2015) Mir ( 2008) Huang ( 2014) Suzuki ( 2008) Rahimi (2019) Jiang-hua ( 2014) He ( 2014) Niu ( 2017) Hesari ( 2018) Chou (2006) Liu ( 2013) Lin ( 2004) Mohammadzadeh ( 2020) Yu ( 2007) Shrubsole ( 2004) Deligezer ( 2005) Kaya ( 2016) Pooja ( 2015) Hekim (2007) Hedayatizadeh ( 2017) Zhang ( 2015)…”

“…Biochemical Genetics (2021) 59:367-397 2015; Prasad and Wilkhoo 2011;Rahimi et al 2019;Sangrajrang et al 2010;Shrubsole et al 2004;Song et al 2016;Suzuki et al 2008;Waseem et al 2016;Weiner et al 2010;Weiwei et al 2014;Yu et al 2007;Zhang et al 2015) were found to be eligible based on inclusion criteria for the current meta-analysis. Figure 1 shows the flowchart of how the studies were identified and then selected step by step.…”

“…1 The flowchart of, step by step, the study identification and selection process 11, 12, and 22 show the frequency of the common homozygote, heterozygote, and rare homozygotes, respectively (for the C677T polymorphism: 1 is the C-allele, and 2 is the T-allele and for the A1298C polymorphism: 1 is the A-allele and 2 is the C-allele) *A P-value < 0.05 in HWE's test was indicated not to be in agreement with HWE **A value of 7 or more was considered to have a high level of quality and studies on A1298C polymorphism. The included studies were published between 2003 (Ergul et al 2003) and 2019 (Rahimi et al 2019).…”